ARHGAP1: A Potential Drug Target and Biomarker for GTPase-Inhibition

Target Name: ARHGAP1

NCBI ID: G392

ARHGAP1

ARHGAP1: A Potential Drug Target and Biomarker for GTPase-Inhibition

Guanosine triphosphate (GTP) is a crucial molecule in intracellular signaling, playing a pivotal role in various cellular processes, including intracellular signaling, protein-protein interactions, and intracellular transport. The GTPase enzyme is a key intermediate in the GTP cycle, catalyzing the conversion of GTP to GDP and releasing phosphate groups to downstream effectors. GTPase inhibitors have been shown to have a wide range of therapeutic potential, including the treatment of various neurodegenerative diseases and conditions, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

ARHGAP1: A GTPase-Inhibitor

The ARHGAP1 gene is located on chromosome 18q21 and encodes a protein named Arhgap1. Arhgap1 is a 21-kDa protein that plays a critical role in regulating GTPase activity. It is a member of the ARHGAP family, which includes several similar proteins, including ARHGAP2, ARHGAP3, and ARHGAP4. These proteins are involved in regulating various cellular processes, including intracellular signaling, protein-protein interactions, and intracellular transport.

ARhgap1 is a GTPase inhibitor that inhibits the activity of the protein GTPase. GTPase inhibitors have been shown to have a wide range of therapeutic potential, including the treatment of various neurodegenerative diseases and conditions, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The use of GTPase inhibitors as therapeutic agents has been shown to improve clinical outcomes in various patient populations, including those with neurodegenerative diseases.

ARhgap1 has been shown to have a wide range of physiological functions. It is involved in regulating the activity of several cellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. ARhgap1 has also been shown to play a critical role in regulating cellular processes that are important for tissue growth and development, such as cell migration and cell survival.

ARhgap1 has been shown to have a wide range of potential drug-like compounds that can be used to treat various neurodegenerative diseases and conditions. For example, several studies have shown that ARhgap1 inhibitors can be effective in treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These compounds have been shown to improve clinical outcomes in patient populations, including improved cognitive function, reduced neurodegeneration, and increased survival.

ARhgap1 as a Potential Drug Target

The ARhgap1 gene has been shown to be involved in several cellular processes that are important for the development and progression of neurodegenerative diseases. Therefore, it is a potential drug target for the treatment of these conditions.

ARhgap1 has been shown to play a critical role in the regulation of cellular signaling pathways that are important for the development and progression of neurodegenerative diseases. For example, studies have shown that ARhgap1 is involved in the regulation of the TGF-β pathway, a pathway that is involved in the development and progression of many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition, ARhgap1 has been shown to play a critical role in the regulation of cellular signaling pathways that are important for the development and progression of neurodegenerative diseases, such as the PI3K/Akt pathway. This pathway is involved in the regulation of many cellular processes that are important for

Protein Name: Rho GTPase Activating Protein 1

Functions: GTPase activator for the Rho, Rac and Cdc42 proteins, converting them to the putatively inactive GDP-bound state. Cdc42 seems to be the preferred substrate

The "ARHGAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets